Home >  Investors Relations >  Financial Information >  SEC Filings

News Releases

  • December 23, 2019 at 8:30 AM EST
    Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , Dec. 23, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S.
  • December 19, 2019 at 8:30 AM EST
    CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA , Dec. 19, 2019 /PRNewswire/ --   CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby
  • December 2, 2019 at 8:02 AM EST
    Product Launch Anticipated in the First Quarter 2020 ATLANTA , Dec. 2, 2019 /PRNewswire/ --   CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally
  • December 2, 2019 at 8:00 AM EST
    First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA , Dec. 2, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY),   a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside
  • October 30, 2019 at 4:05 PM EDT
    ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ®
  • October 16, 2019 at 4:35 PM EDT
    ATLANTA , Oct. 16, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 third quarter financial results will be released on Wednesday, October 30, 2019 after the market closes.
  • September 18, 2019 at 8:34 AM EDT
    ATLANTA , Sept. 18, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat with analysts and investors at the upcoming Deutsche Bank 27 th Annual Leveraged Finance
  • September 11, 2019 at 4:03 PM EDT
    Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET ATLANTA , Sept. 11, 2019 /PRNewswire/ --  CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery
  • August 29, 2019 at 8:34 AM EDT
    ATLANTA , Aug. 29, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences. CryoLife's management will be presenting at the Morgan Stanley 17th Annual
  • July 30, 2019 at 4:05 PM EDT
    ATLANTA , July 30, 2019 /PRNewswire/ --  Second Quarter and Recent Business Highlights: Total revenues were $71.1 million in the second quarter of 2019, reflecting year over year growth of 4% and a 7% increase on a non-GAAP constant currency basis, both compared to the second quarter of 2018